SCHEMBL6132496

SCHEMBL6132496

CCC1CCC(N2CCN(c3ccc(-c4ccc(C(=O)O)cc4)cc3)CC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
USP2 O75604 1/20 0.51
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
ALOX15 P16050 1/20 0.49
CHEK1 O14757 2/20 0.48
KDM4E B2RXH2 4/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MBTD1 Q05BQ5 1/20 0.43
TP53BP1 Q12888 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132600 1.00 KMT2A (0.59) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL6132491 1.00 KMT2A (0.59) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL6132305 0.87 KMT2A (0.56) KMT2AMEN1ITGB3ITGA2BALOX15
SCHEMBL6132443 0.87 KMT2A (0.56) KMT2AMEN1ITGB3ITGA2BALOX15
SCHEMBL6132302 0.87 KMT2A (0.56) KMT2AMEN1ITGB3ITGA2BALOX15
SCHEMBL6135516 0.86 USP2 (0.67) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL6134910 0.86 USP2 (0.67) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL6134907 0.86 USP2 (0.67) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL1305974 0.85 USP2 (0.63) KMT2AMEN1USP2ITGB3ITGA2B
SCHEMBL6132350 0.84 MEN1 (0.74) KMT2AMEN1USP2ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 KMT2A 4695/4885MEN1 1517/4885USP2 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.